3-methyl-1-(N-morpholino)-2-butanone | 67082-23-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 3-methyl-1-(N-morpholino)-2-butanone
• 英文别名: 3-methyl-1-morpholin-4-yl-butan-2-one；3-Methyl-1-morpholin-4-ylbutan-2-one
• CAS: 67082-23-9
• 化学式: C₉H₁₇NO₂
• 分子量: 171.239
• InChiKey: MPCGGDHXWVCFCX-UHFFFAOYSA-N

物化性质

• 沸点：
  77-78 °C(Press: 2 Torr)
• 密度：
  1.0050 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  吗啉 、 2-isopropyl-3-nitro-oxirane 生成 3-methyl-1-(N-morpholino)-2-butanone
  参考文献：
  名称：

  Sokolov,N.A. et al., Journal of Organic Chemistry USSR (English Translation), 1978, vol. 14, p. 478 - 479

  摘要：

  DOI：

文献信息

• BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF
  申请人：Agency for Science, Technology and Research

  公开号：US20140371199A1

  公开（公告）日：2014-12-18

  The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.

  本发明涉及某些化合物（例如咪唑吡嗪、咪唑吡啶、咪唑吡嗪和咪唑嘧啶化合物），这些化合物作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物制备用于预防和治疗疾病（例如增生性疾病（例如癌症）、炎症性疾病、阿尔茨海默病）的药物的用途，以及治疗这些疾病的方法。
• MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES
  申请人：THE UNIVERSITY OF BRITISH COLUMBIA

  公开号：US20180221279A1

  公开（公告）日：2018-08-09

  Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.

  本文提供了适用于装载到脂质体纳米粒载体中的药物衍生物。在一些首选方面，这些衍生物包括一种水溶性较差的药物衍生物，其与一种弱碱基团衍生化，有助于通过LN跨膜pH或离子梯度将药物活性地装载到LN的水相内部。弱碱基团可以选择性地包括一个亲脂性结构域，有助于将药物活性地装载到脂质体膜的内单分子层。优点是，药物衍生物的LN配方相对于相应的游离药物表现出改善的溶解度、降低的毒性、增强的疗效和/或其他优点。
• [EN] BIS(DIAZIRINE) DERIVATIVES AS PHOTO-CROSSSLINKER FOR TREATING CORNEAL ECTATIC DISORDERS<br/>[FR] DÉRIVÉS DE BIS(DIAZIRINE) UTILISÉS EN TANT QU'AGENT DE PHOTO-RÉTICULATION POUR LE TRAITEMENT DE TROUBLES ECTASIQUES DE LA CORNÉE
  申请人：AVEDRO INC

  公开号：WO2020154673A1

  公开（公告）日：2020-07-30

  This disclosure features bis(diazirine) derivatives of the formulae (I) (l-a) or (l-b) that generate cross-linking in the cornea in response to exposure to an electromagnetic irradiation (e.g. UV-light). The compounds are useful, e.g. for treating a subject (e.g. a human) having a disease, disorder or condition in which abnormal shaping of the cornea (e.g. thinning of the cornea, e.g. bilateral thinning of the cornea, e.g. bilateral thinning of the central, paracentral, or peripheral cornea, or steepening (e.g., bulging) of the cornea) contributes to the pathology and/or symptoms, and/or progression of the disease, disorder or condition. Examples of such diseases, disorders or conditions include: (i) corneal ectatic disorders; (ii) vision conditions; and (iii) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular examples of such diseases, disorders or conditions include keratoconus, keratoglobus, pellucid marginal degeneration, corneal ectasia (e.g. postoperative ectasia, e.g. post-LASIK ectasia), Terrien's marginal degeneration, myopia, hyperopia, astigmatism, irregular astigmatism and presbyopia. In some embodiments, the claimed methods can be performed in the absence of added or supplemental oxygen levels, which can be advantageous in some applications. Preferred exemplary compounds are e.g. bis(diazirine) amino acid derivatives, such as e.g. example 1:

  这份披露涉及到式(I) (l-a)或(l-b)的双(重氮基)衍生物，当暴露于电磁辐射（例如紫外光）时，在角膜中产生交联作用。这些化合物可用于治疗患有疾病、疾病或病况的受试者（例如人类），其中角膜的异常形态（例如角膜变薄，例如角膜双侧变薄，例如角膜中央、副中央或周边变薄，或角膜变陡（例如突出））导致病理和/或症状的发生，以及/或疾病、疾病或病况的进展。此类疾病、疾病或病况的示例包括：(i) 角膜扩张性疾病；(ii) 视力状况；以及(iii) 与前述任何疾病、疾病或病况或本文所披露的任何内容相关的后遗症或共病。此类疾病、疾病或病况的更具体示例包括角膜锥状变性、角膜球状变性、边缘淡化变性、角膜扩张（例如术后扩张，例如术后LASIK扩张）、Terrien边缘变性、近视、远视、散光、不规则散光和老视。在某些实施例中，声称的方法可以在没有额外或补充氧气水平的情况下进行，这在某些应用中可能是有利的。优选的示例化合物包括双(重氮基)氨基酸衍生物，例如示例1：
• HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
  申请人：GiraFpharma LLC

  公开号：US20190023666A1

  公开（公告）日：2019-01-24

  Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

  提供了氨基吡嗪化合物作为腺苷受体的调节剂。这些化合物可能作为治疗经由G蛋白偶联受体信号通路介导的疾病的治疗剂，并且可能在肿瘤学中发挥特定作用。
• PROGESTERONE ANALOGS AND USES RELATED THERETO
  申请人：Emory University

  公开号：US20130210785A1

  公开（公告）日：2013-08-15

  This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.

  该披露涉及孕酮衍生物及其相关用途。在某些实施例中，该披露涉及本文披露的化合物及其用途，用于管理由创伤性脑损伤或中风引起的炎症。